MyBlueDots

ESSEX, Conn.–(BUSINESS WIRE)– #BLT1–Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD), Crohn’s disease and ulcerative colitis, today announced that the company has secured an additional $8.975 million in program-related investment funding in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust (“Helmsley”), bringing Helmsley’s t

BASEL, Switzerland–(BUSINESS WIRE)–Demonstrated Robust Dose-Dependent Target Engagement, Preliminary Evidence of Improved Organ Function and a Favorable Safety Profile

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate at the 43rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT. A live webcast of the presentat

MILAN, Italy & MORRISTOWN, New Jersey & SEOUL, Republic of Korea–(BUSINESS WIRE)—- $NWRN #schizophrenia–Newron and Myung In Pharm, South Korea’s leading specialist CNS pharma company, announce license agreement for evenamide in South Korea.

BOSTON–(BUSINESS WIRE)–PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

MELVILLE, N.Y.–(BUSINESS WIRE)–Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers throughout California that the Henry Schein Customer Emergency Support Hotline is open for dental and medical professionals who may experience operational, logistical, or financial issues as a result of damage caused by the ongoing fires. The toll-free number for all Henry Schein customers is 800-999-9729. The hotline is open 24/7, with real-time assistance available from Team Schein Members from 8 a.m. to

SEATTLE–(BUSINESS WIRE)–Cyrus Biotech today announced that its protease CYR212 has been selected as its clinical candidate for chronic IgG-driven autoimmune diseases.